Journal of Clinical Oncology, Volume 44, Issue 22, Page 2110-2120, August 2026.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine.

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy.

In the ICU, a resident is surrounded by deaths, each one leaving him with a sense of emptiness. Then a Christmas tragedy highlights medicine’s privilege of bearing witness to love as well as death.

For decades, pancreatic ductal adenocarcinoma (PDAC) has been perhaps the clearest example of a cancer that is driven by a dominant oncogenic event yet is resistant to therapeutic exploitation. More than 90% of pancreatic cancers harbor activating RAS mutations, most commonly those involving KRAS codon 12,...

For more than two decades, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy has been the standard of care for muscle-invasive bladder cancer. Despite this approach, relapse rates have remained high and long-term survival gains have been modest. The treatment landscape began to shift with the NIAGARA trial, which showed a...

Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide therapy was similar to that with indefinite therapy. Adverse events and second cancers were more common with indefinite therapy.

Multiple myeloma has undergone a therapeutic revolution at a pace nearly unmatched in oncology. Yet amid these advances, a key assumption in multiple myeloma therapy persists: more and longer treatment is better. The trial by Kumar and colleagues (ENDURANCE), reported in this issue of the Journal,1 ...

This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies.

After total hip or knee arthroplasty, aspirin alone was noninferior to rivaroxaban followed by aspirin in preventing symptomatic venous thromboembolism, with a similarly low risk of bleeding complications.

A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft.

Among patients with resected ALK-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib.

An ICU physician believed letting her father die at home meant comfort, dignity, control, family close by, and the quiet reassurance of hospice. But she didn’t realize what it would require of her family.

A 42-year-old man with a recent stem-cell transplant presented with a 2-week history of urinary frequency and weak stream. Papules were seen on the penile shaft. Urethroscopy showed papillomatous lesions on the urethral mucosa.

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but an increased risk of grade 3 or higher adverse events.

Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them?

In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days.

Among 38 patients who received CAR T-cell therapy for refractory or relapsed B-cell lymphomas, lymphoma-free survival at 10 years was 32% for large B-cell lymphomas and 47% for follicular lymphoma.

Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,...

The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences.

A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing.

Aug 9 marks the UN's International Day of the World's Indigenous Peoples. Although Indigenous Peoples represent just 6% of the global population, they make up more than 15% of individuals living in extreme poverty worldwide. Indigenous Peoples have a holistic view of health, comprising spiritual, environmental, cultural, and social dimensions. However, poor understanding and incorporation of these concepts into Western medicine, alongside institutional bias and the legacy of colonisation, have led to persistent health disparities between Indigenous Peoples and non-Indigenous counterparts across a spectrum of diseases and cancer is a prime example.

In contemporary management of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, it is standard to switch therapies at tumour progression, defined by RECIST criteria in clinical trials, and by other measures (many, ironically, considered non-measurable by RECIST) in clinical practice, including subtler radiological changes, findings on examination, rising tumour markers, or increased symptoms related to cancer.1 Accordingly, in the clinic, a treatment change can be considered for symptomatic progression despite radiologically stable disease, or the same treatment might be continued beyond asymptomatic oligoprogression.

The recently reported SUPREMO trial evaluated chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. Although chest wall radiotherapy did not improve overall survival, local recurrence was reduced (hazard ratio [HR] 0·45 [95%CI 0·20 to 0·99]), with an absolute benefit of just under 2%.1 With improving outcomes in modern breast cancer therapy, such incremental gains must be weighed against the burden of treatment-related toxicity. In this regard, Galina Velikova and colleagues2 are to be commended for their successful effort to include patient-reported quality of life (QOL) as a key component of the SUPREMO trial.

Randomised trials in rare cancers are scarce, and those that achieve adequate enrolment and methodological rigour warrant recognition. Upper tract urothelial carcinoma, which comprises only 5–10% of urothelial malignancies, presents unique challenges for trialists because of its low incidence and heterogeneous presentation. Despite its rarity, however, upper tract urothelial carcinoma carries a disproportionately high risk of bladder recurrence after radical nephroureterectomy, affecting 22–47% of patients in contemporary series.

For patients with high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, therapeutic decision making remains challenging. Radical cystectomy offers the most reliable oncological control, but at the cost of major surgery, urinary diversion, and lasting effects on quality of life. Bladder-sparing approaches are therefore attractive, particularly if they provide durable disease control without compromising the opportunity for cure. Against this backdrop, the results of BOND-003 Cohort C reported by Mark Tyson and colleagues in The Lancet Oncology enter a rapidly evolving treatment landscape.

Radioactive iodine-refractory differentiated thyroid cancer remains a therapeutically challenging disease despite important advances over the last decade. Multi-kinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) signaling have improved progression-free survival compared with placebo,1–3 and these inhibitors are now considered standard of care for patients with locally advanced or metastatic disease.4 However, these therapies are associated with substantial toxicity, and durable responses remain uncommon.

Preoperative fluoropyrimidine-based chemoradiotherapy constituted the cornerstone in the management of locally advanced rectal cancer for more than two decades. Randomised trials established chemoradiotherapy followed by total mesorectal excision surgery as a standard approach, improving local control compared with radiotherapy alone and offering advantages, especially with regard to toxicity, over postoperative chemoradiotherapy. Despite these advances, distant metastases remained the predominant cause of treatment failure.

Gastric cancer remains a major cause of cancer mortality, and prognosis is particularly poor in individuals with peritoneal metastases.1,2 Although the integration of immunotherapy and targeted agents—such as trastuzumab or zolbetuximab—into systemic chemotherapy has improved survival in selected populations,3,4 treatment for these patients remains a clinical challenge, prompting the exploration of aggressive locoregional strategies.

In a post-hoc analysis of the PACIFIC trial published in The Lancet Oncology, Leonardo Brunetti and colleagues1 found that baseline proton pump inhibitor and antibiotic use was associated with worse progression-free survival in patients with stage III non-small-cell lung cancer (NSCLC) treated with durvalumab after chemoradiotherapy, but not in those treated with placebo. This treatment-specific effect suggests an interaction with immunotherapy that is potentially mediated by microbiome disruption.

Ward and colleagues1 offer a sophisticated simulation of 17 cancer typesacross 200 countries. The authors’ projections of persistent survival disparities are likely correct in direction (ie, Africa and Asia have lowest survival, North America and Oceania have highest survival). However, the model's architecture raises concerns that warrant scrutiny, not to dismiss the work, but to ensure policy influence is proportionate to evidentiary weight.

We thank Atif Kamal for his engagement and agree that investment in population-based cancer registries is important, especially when data are scarce.

Varey AHR, Weitemeyer MB, Gjorup CA, Lo SN, Williams GJ, Thompson JF. Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis. Lancet Oncol 2026; 27: 452–60—In this Article, the PROSPERO registration number stated in the Summary and main text Methods should have been CRD42023494671. This correction has been made as of July 27, 2026.

The Royal College of Physicians (RCP) is calling upon the UK Government to address the nation's air pollution as a public health emergency, and not simply an environmental issue.

The 2026 G7 meeting of world leaders was held June 15–17 at Évian-les-Bains, Haute-Savoie, France, and hosted by President Emmanuel Macron of France. But among the usual high level political talks was a surprise announcement—a call to action on cancer. The leaders of the G7 nations of Canada, France, Germany, Italy, Japan, the UK, and the USA—together with this meeting's guest nations of Brazil, Egypt, India, Kenya, and South Korea—issued the statement committing to “deepen international scientific cooperation, close persistent gaps in prevention and early detection, and ensure that progress in oncology reaches every patient”.

In June, 2026, a Working Group of 23 scientists from 13 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of butyl benzyl phthalate (BBzP), dibutyl phthalate (DBP), and diisononyl phthalate (DINP).

Although substantial progress against cancer has been made by the USA over the past several decades, cancer-related disparities remain a crucial public health challenge in the country, suggests the Cancer Disparities Progress Report 2026, released by the American Association for Cancer Research (AACR; Philadelphia, PA, USA) on June 24, 2026.

South Africa's completion of its first imPACT Review has raised hopes that long-standing gaps in cancer care could be translated into a new national cancer control plan, but clinicians and advocates caution that its value depends on whether it leads to funded implementation across the country's fragmented health system.

Addressing the persistent increase in rates of overweight, obesity, and physical inactivity in children and adolescents living in the WHO Americas Region, the Pan American Health Organization (PAHO) and the Organization of American States (OAS; Washington, DC, USA) have released new guidelines to assist countries in the region in developing, executing, monitoring, and assessing policies that foster healthy eating and physical activity in school environments.

The expansion of colorectal cancer screening in Ontario, Canada, has coincided with new evidence showing that registered First Nations people experience higher colon cancer incidence at younger ages and poorer survival after breast, cervical, and colon cancer diagnoses than other residents.

Effective cancer control depends on the coordinated functioning of multiple interlocking systems, including regulation, workforce planning, research collaboration, supply chains, and clinical infrastructure. Disruption in any of these can have downstream consequences for cancer outcomes, making the field particularly sensitive to structural, political, and policy changes.

Trastuzumab rezetecan improved progression-free survival versus pyrotinib plus capecitabine and showed a distinct safety profile in patients with HER2-positive breast cancer, presenting as a potential new treatment option.

Switching to camizestrant plus CDK4/6 inhibitor at ESR1 mutation emergence, versus continuing aromatase inhibitor plus CDK4/6 inhibitor, resulted in sustained progression-free survival benefit that translated into a statistically significant improvement in second progression-free survival. These results further support switching endocrine treatment to camizestrant from aromatase inhibitor upon detection of ESR1 mutation, with continuation of any of the globally approved CDK4/6 inhibitor, to extend first-line treatment benefit.

The 5-year QOL findings showed worse chest wall toxicity and no effect on other QOL domains. The subgroup analyses suggested a potential negative effect of chemotherapy and axillary clearance after sentinel node biopsy.

A single, postoperative pirarubicin instillation after radical nephroureterectomy is an efficacious treatment with manageable adverse events to reduce recurrence in patients with upper tract urothelial carcinoma.

Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events. Cretostimogene shows promise as an innovative bladder-sparing treatment for high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ.

In previously-treated patients with locally advanced or metastatic, radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer, dabrafenib plus trametinib showed significant benefits for progression-free survival and overall response rate, with no new safety signals. These findings support the second-line use of dabrafenib plus trametinib in patients with radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer.

For MRI-defined, high-risk, locally advanced rectal cancer, the addition of irinotecan to standard of care did not improve outcomes and should not be used in combination with radiotherapy plus capecitabine.

In patients with dMMR or MSI-H locally advanced colorectal cancer, neoadjuvant toripalimab plus celecoxib significantly increased the proportion of patients attaining pathological complete response compared with toripalimab monotherapy, with a similar safety profile. These findings support further investigation of this combination strategy in larger phase 3 trials.

Gastrectomy with cytoreductive surgery and HIPEC provided no survival benefit in patients with gastric cancer and limited peritoneal metastases compared with systemic therapy alone.

Baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes with durvalumab, but not with placebo, consistent with potential attenuation of the benefit of durvalumab with proton pump inhibitors and antibiotics in patients with unresectable stage III NSCLC.

Cancer incidence and mortality are rising globally, with their burden falling disproportionately on low-income and middle-income countries. Africa faces major gaps in oncology education and workforce development, limiting access to high-quality cancer care. Focusing on efforts relevant to oncology in Africa, we provide an overview of existing programmes and models for educating health-care personnel in resource-constrained regions, highlighting challenges and effective strategies. Current efforts described include formal curricula, fellowship programmes, mentorship networks, and technology-driven solutions such as e-learning and telemedicine.

The rigorous conduct of well designed clinical trials is critical to improving outcomes for patients with gynaecological cancers. The Gynecologic Cancer InterGroup (GCIG) has promoted collaboration and harmonisation to guide clinical trials in ovarian and endometrial cancer through a series of consensus meetings with published statements. GCIG convened the inaugural Cervical Cancer Consensus Conference in Clinical Research in Dublin, Ireland, on Oct 14–15, 2024, to develop a consensus on design elements, essential questions, and unmet needs in cervical cancer research.

Somatostatin receptor PET imaging is integral to the management of patients with neuroendocrine tumours (NETs), yet standardised criteria for therapy response assessment with the use of this modality are not available. This Policy Review reports the development of the European Neuroendocrine Tumor Society somatostatin receptor PET response assessment framework, established through a structured modified Delphi process coordinated by the European Neuroendocrine Tumor Society. 34 international experts from nuclear medicine, radiology, oncology, endocrinology, surgery, and related disciplines participated in four iterative rounds evaluating 76 statements, with consensus defined as at least 75% agreement.

The analysis failed to show a significant benefit of WLI in patients with lung‐metastatic RMS, apart from the subgroup of patients older than 10 years. Lung‐RFS was not influenced by WLI.

Vobramitamab duocarmazine demonstrated modest antitumor activity across tumor types, with the most pronounced activity in mCRPC. Treatment was limited by toxicity, particularly pleural effusions and fatigue, which restricted dosing duration. Study treatment was discontinued to refocus on mCRPC in a randomized phase 2 study (TAMARACK/NCT05551117), which was later discontinued after assessment of the vobramitamab duocarmazine safety and efficacy profile.

Loncastuximab tesirine shows clinically meaningful activity in heavily pretreated R/R DLBCL, including post–CAR T‐cell therapy settings, with frequent but manageable cytopenias. Pooled estimates showed substantial heterogeneity, driven mainly by real‐world cohorts, and should be interpreted with caution.

This study establishes a modern expectation of outcome of Ph‐positive B‐cell ALL treated in salvage 1. Third‐generation TKI plus blinatumomab combinations should be given consideration in this setting.

This cohort study investigates tumor-infiltrating clonal hematopoiesis in solid tumors and evaluates its association with clinical factors and overall survival.

This cohort study characterizes the prevalence of treatment for metastatic non–small cell lung cancer and predictors of its receipt over a time span ranging from when empiric cytotoxic regimens dominated to the recent availability of targeted therapies and immunotherapy.

This cohort study investigates whether the potential association of modifiable risk factors with prostate cancer varies across genetic risk profiles and age.

This cross-sectional study investigates treatment delays in patients with early age–onset colorectal cancer and determines targetable factors contributing to delayed therapy.

This randomized clinical trial examines whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in gastric cancer with peritoneal metastasis.

This cohort study analyzes longitudinal rates of and factors associated with suicidal self-directed violence among veterans with cancer.

This meta-analysis compares survival with programmed cell death 1 protein or programmed cell death 1 ligand 1 (PD-[L]1) inhibitor monotherapy vs chemoimmunotherapy in treatment-naive patients with advanced NSCLC and high PD-L1 expression.

This descriptive surveillance study examines the percentage of lung cancer cases diagnosed at an early stage, visualizing temporal patterns with heat maps.

This decision analytical model study evaluates the effects of relabeling grade group 1 prostate cancer on prostate cancer mortality in the US.

This cohort study examines the association between prostate-specific membrane antigen positron emission tomography use and initial prostate cancer treatment.

This review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage breast cancer.

This Viewpoint discusses concerns with the current grading of cutaneous toxic effects in Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 and proposes an updated framework.

This essay discusses the author’s experience as a physician in Beirut during wartime.

As of June 3, WHO Director-General Tedros Ghebreyesus reported 344 confirmed cases of Ebola virus disease in DR Congo, as well as 15 confirmed cases in Uganda. Encouragingly, suspected cases in the DR Congo have fallen, as efforts continue to eliminate delays in testing. However, this outbreak, caused by Bundibugyo virus (Orthoebolavirus bundibugyoense), highlights a recurring vulnerability in epidemic preparedness: limited access to reliable and accurate diagnostics and absence of specific treatments and vaccines.

For decades, paediatric anticoagulation has been guided more by extrapolation than by evidence. Treatments for venous thromboembolism in children have largely mirrored adult practice, despite fundamental developmental differences in haemostasis and drug handling. The emergence of direct oral anticoagulants (DOACs) marks a turning point, with the first generation of trials specifically designed for paediatric populations published in the past 5 years. Within this context, the study by Leonardo R Brandão and colleagues1 provides timely and important data on apixaban in children with venous thromboembolism.

Edel Y, Stein PE, Kawtharany H, et al. Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network. Lancet Haematol 2026; 13: e338–50—In this Review, the list of countries in the first paragraph of the Methods section should contain Norway and not Denmark. This change has been made on May 27, 2026.

Donzel M, Khedimallah S, Barriere S, et al. Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study. Lancet Haematol 2026; 13: e396–407—In this Article, Agathe Gouband and Damien Luque Paz's affiliation should have been “Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France”, and their degrees should have been PharmD. In addition, the acknowledgments should read “We thank the FIMBANK network, funded by the French Institut National du Cancer (INCa BCB 2013 & 2022), for providing data for some of the patients included in the present study.” These corrections have been made to the online version as of July 2, 2026.

In 2025, the European Medicines Agency and the Heads of Medicines Agencies issued recommendations to address vulnerabilities in the supply of anti-RhD immunoglobulin (RHIG; used to prevent RhD alloimmunisation during pregnancy). This alert highlights a broader but under-recognised problem: the fragile global supply of hyperimmune immunoglobulins, a group of plasma-derived medicines essential for post-exposure prophylaxis (PEP) and maternal–child health. Despite their various inclusions in the WHO Model Lists of Essential Medicines for adults and children and in national lists, these products remain vulnerable to shortages and fragmented procurement in both high-income countries (HICs) and low-income and middle-income countries (LMICs).

With its museums, art galleries, and a castle that dominates the skyline, it is little wonder that Edinburgh, UK, is ranked regularly among the most popular global destinations for tourists. Yet if visitors look beyond the most famous attractions—such as the Palace of Holyroodhouse, the Royal Yacht Britannia, and the Royal Botanic Garden—then Scotland's capital city boasts a plethora of destinations that lie off the beaten track. One of those hidden gems is the Physicians’ Gallery on Queen Street, a free museum in which the Royal College of Physicians of Edinburgh (RCPE) hosts exhibitions drawn from its library of more than 85 000 books, journals, pamphlets, and other items, supplemented with exhibits borrowed from other collections.

Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted.

Inotuzumab ozogamicin showed high activity as reinduction treatment in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse and a favourable toxicity profile with no treatment-related deaths.

Our findings could assist clinicians in delivering more targeted and timely supportive care interventions and might inform patients about anticipated symptoms during the early post-CAR T-cell infusion period. Moreover, the observed discrepancies between patient-reported and clinician-reported symptoms suggest that more systematic use of patient-reported outcome measures might provide complementary insights beyond those captured through clinician assessment.

In this descriptive study, the safety and efficacy profile of a fixed-dose-by-bodyweight-tier apixaban regimen was similar to that of standard of care for the treatment of venous thromboembolism and prevention of venous thromboembolism recurrence in children younger than 18 years, providing a potential additional treatment option in this patient population.

The European Group for Blood and Bone Marrow transplantation Practice Harmonization and Guidelines Committee together with the Lymphoma Working Party convened 23 experts in Hodgkin lymphoma, transplantation, and radiation oncology, to develop consensus recommendations on the use of autologous and allogeneic haematopoietic cell transplantation (HCT) in relapsed or refractory Hodgkin lymphoma. Through a structured literature review and a 2-day workshop in Berlin, Germany, on Sept 29 and 30, 2025, the panel established guidance across major clinical decision points.

Haematologists should be prepared to address several key transitions and timepoints during the female reproductive health lifespan to provide safe and equitable care for all patients with haematological disorders. In this Review, we summarise important points for recognition and consideration in the care of patients with lifelong or transient haematological conditions. We include discussions on menarche, pregnancy, menopause, and gender-affirming care, and how these life transitions might impact people with underlying haematological disorders, including an increased risk of iron deficiency with or without anaemia.

The inpatient classical haematology consult service occupies a specialised, complex, and high-acuity domain in the hospital setting. As three academic classical haematologists practicing primarily or exclusively as inpatient consultants in the US, we describe the wide spectrum of haematological disorders we manage in our practices and the rapidly expanding number and complexity of treatments we have to offer, therefore necessitating a substantial breadth and depth of diagnostic and therapeutic expertise to practice successfully in this setting.

A 25-year-old construction worker with a history of marijuana and cocaine use presented with 3 months of weight loss, fever, night sweats, cough, and progressive dyspnoea. He was transferred to Hospital Alma Mater de Antioquia (Medellín, Colombia) on Nov 20, 2025, after developing haemodynamic instability and worsening hypoxaemia, despite treatment with broad-spectrum antibiotics. Imaging showed a left pleural effusion with lower-lobe atelectasis, generalised lymphadenopathy, and hepatosplenomegaly.

Plasma cell leukemia represents the most aggressive end of the plasma cell neoplasm spectrum. Al Hadidi, van Rhee, and Anderson use case vignettes to highlight the biology and major challenges associated with this poor-prognosis entity. They emphasize the importance of accurate diagnosis and sensitive disease monitoring and explore emerging therapeutic opportunities, focusing particularly on the role of novel immunotherapy strategies.

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant bleeding disorder of the vessel wall due to mutations in genes in the transforming growth factor β signaling pathway that regulate angiogenesis. Al-Samkari et al report the first data from a prospective longitudinal outcomes registry that is shedding new light on the incidence, natural history, and clinical manifestations of HHT. The findings underscore the major health burden that this disease presents from early adulthood; point to gaps in disease recognition, diagnosis, and treatment; and provide much-needed granular information for patients and their physicians.

Central nervous system Langerhans cell histiocytosis is a rare, devastating inflammatory myeloid neoplasm driven by somatic mutations in the MAPK pathway, most frequently the BRAF^V600E mutation. Rajamanickam et al established a high-fidelity in vivo model of its complex pathology using xenotransplantation of human BRAF^V600E-mutant hematopoietic progenitor cells into the brains of immunodeficient mice. They found that these progenitors are hyperproliferative and that the output of mature macrophages is highly inflammatory and apoptosis resistant in this environment, actively driving neuronal loss and reactive astrogliosis.

Genomics is now essential in diagnosis and treatment of most hematological malignancies. It is also a key to better understanding of their biology, yet ready access to large data sets is a barrier to progress. With this in mind, Lu and colleagues report the development of the ASH HematOmics Program (ASHOP), a growing clinically annotated genomics resource that brings together data on nearly 6000 hematological malignancies and lowers the barrier for meaningful exploration of complex molecular profiles. ASHOP is an interactive platform designed to allow users to ask meaningful questions of a substantial data set without the need for advanced coding skills or bespoke computational pipelines. This tool takes data access and sharing to a higher level.

Children with Down syndrome (trisomy 21) have a 150-fold increased risk of developing myeloid leukemia in early childhood, with leukemogenesis initiating in utero. Suzuki and colleagues identified Polycomb repressive complex 2 (PRC2) insufficiency as a unifying epigenetic mechanism in Down syndrome myeloid leukemia. They show that cohesin and PRC2 lesions, together with GATA1 truncating mutations and trisomy 21–associated factors, cooperate to reshape chromatin regulation and drive leukemogenesis.

Iron absorption by the intestine is a major point of regulation of systemic iron store levels and is controlled by liver production of hepcidin. Hepcidin modulates the transcription and activity of the transmembrane iron exporter ferroportin, which is essential for iron absorption. Yu and colleagues discovered that RNF217, an E3 ligase of the ubiquitin-proteasome system, is an additional regulatory point for the expression of ferroportin within the intestinal endothelial cells and a target for therapies that bypass hepcidin to better control iron overload.

It is underappreciated that many plasma coagulation factors perform double cleavage of their substrates to release a series of products. The molecular mechanisms of these multidomain rearrangements require elucidation, and Stojanovski et al report a new cryogenic electron microscopy (cryo-EM) structure of the prothrombinase complex bound to meizothrombin, a partially activated species of thrombin. This arrangement promotes a secondary proteolytic cleavage to release fully activated thrombin at R271, further elucidating how thrombin is generated during thrombosis.

Can we improve donor selection in allogeneic hematopoietic cell transplantation by going beyond matching classical HLA class I and II loci? Petersdorf and colleagues identified class III variants within extended major histocompatibility complex haplotypes as a determinant of mortality and relapse after haploidentical transplantation. Their work expands the genetic framework used to assess transplant risk and is applicable for refining donor selection among potential family donors.

New England Journal of Medicine, Volume 395, Issue 4, Page 338-348, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 362-373, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 374-387, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 411-413, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 408-410, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 405-408, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 402-404, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 388-388, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 389-398, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 319-321, July 23, 2026.

New England Journal of Medicine, Volume 395, Issue 4, Page 313-316, July 23, 2026.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

The Imaging and Radiation Oncology Core (IROC) works with the Children’s Oncology Group (COG) to provide institutional credentialing and patient radiotherapy plan review for sites that enroll patients on COG clinical trials. COG protocols that include radiotherapy require specific site credentialing activities depending on the treatment technique that is allowed in the protocol. In addition, there are protocol-specific treatment planning guidelines for tumor coverage and normal tissue sparing that define not only protocol acceptable limits, but also variations in limits if deemed clinically necessary, as well as protocol deviations.

Minimizing Radiation-Induced-Lymphocyte-Kill (RILK), a key immune-suppressive effect of Radiation Therapy (RT) to augment tumor-specific immunity is timely and important. We assessed RT dose sparing to blood/immune-rich organs beyond Radiation-Therapy-Oncology-Group (RTOG) criteria, and its effect on RILK, and adverse events.

Relationships between radiation therapy (RT) dose to cardiac substructures and patient-reported outcomes, as assessed by health-related quality of life (HRQOL), remain unknown. We sought to: (1) compare RT dose to cardiac substructures in patients treated with proton versus photon RT on the Radiotherapy Comparative Effectiveness (RadComp) pragmatic randomized clinical trial, which compared proton versus photon RT in breast cancer; (2) evaluate whether there were changes in HRQOL outcomes from baseline to 6 months following RT; and (3) determine the potential associations between radiation dose-volume histogram (DVH) parameters and changes in cardiac-related HRQOL.

There is substantially heterogeneous use of luteinizing hormone-releasing hormone analogues (LHRHa) with or without first-generation non-steroidal anti-androgens (NSAA, e.g. bicalutamide) during radiation for localized prostate cancer. The primary objectives of this study were to determine the impact of NSAA on overall survival (OS), other cause mortality (OCM) and toxicity.

Decline of quality of life (QOL) and cognitive function is common for brain metastases patients receiving radiotherapy but there is currently no standard of care for addressing those symptoms. This phase 2 randomized controlled trial examined the efficacy of early neuropsychological evaluation and integration to preserve QOL and cognition for patients treated with radiation for brain metastases.

To determine the maximum-tolerated dose (MTD) of dose-escalated hypofractionated adaptive radiation therapy with atezolizumab in patients with head and neck squamous cell carcinomas (HNSCCs) in a phase 1 trial.

To compare the safety and efficacy of preoperative simultaneous integrated boost chemoradiotherapy (SIB-CRT) versus standard chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC).

In patients who received breast-conserving surgery (BCS) for early-stage breast cancer, the present study assessed acute and short-term side effects and oncological outcomes after whole breast irradiation (WBI) with an ultra-hypofractionated schedule.

Ultra-high dose rate (>40 Gy/s, FLASH) radiation therapy (RT) provides equivalent tumor control while reducing normal tissue toxicity relative to conventional dose rate (CONV) RT. However, the mechanisms underlying the observed FLASH effect are unknown. We hypothesized that the preservation of mitochondrial integrity in nontumorigenic cells by FLASH RT could be a key factor in reducing normal tissue toxicity and improving overall treatment outcomes.

While QOL generally declined the most among all arms at 6 weeks post RT start, and remained lower than baseline at 5 years, there were no clinically significant differences in QOL among arms at 1 and 5 years. QALYs for freedom from progression favored STADT + PLNRT + PBRT for salvage treatment of prostate cancer.

Limited data are available on outcomes of patients with spinal metastases treated with separation surgery with postoperative stereotactic body radiation therapy (SBRT).

The role of neoadjuvant concurrent chemoradiation therapy (NACCRT) with anti-HER2 therapy in locally advanced breast cancer (LABC) remains unexplored. We conducted a phase II randomized trial to evaluate whether NACCRT combined with trastuzumab improves pathological complete response (pCR) compared with standard neoadjuvant chemotherapy (NACT) in patients with HER2-positive inoperable LABC.

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy among men worldwide and remains a leading cause of cancer-related mortality.1 High-risk prostate cancer (HR-PC), defined by elevated prostate-specific antigen (PSA > 20 ng/mL), high Gleason score (grade group 4 or 5), or advanced clinical stage (≥ T3a), accounts for approximately 15–20% of new diagnoses and is associated with increased risks of recurrence, metastasis, and cancer-specific death.2,3

We sought to identify predictors of radiation oncology (RO) practice site disappearance in the United States between 2018-2025, characterize how turnover reshapes county-level treatment capacity, and understand how counties with versus without RO access in 2025 differed in terms of sociodemographic and health system features.

to evaluate predictive dosimetric factors for fat necrosis (FN) after post-operative single-fraction stereotactic partial breast irradiation (S-PBI) in early-stage breast cancer.

Accurate prediction of symptomatic radiation pneumonitis (RP) is critical for radiotherapy, yet the generalization of deep learning models is hindered by restricted access to multi-center data. Although federated learning (FL) bypasses data-sharing restrictions, standard FL algorithms underperform on highly heterogeneous clinical data across institutions. Therefore, this study aims to evaluate the clinical feasibility of a center-specific federated learning approach.

As reported in the Journal of Cancer Education by Kim et al, parallel surveys of cancer survivors and cancer care providers showed gaps in risk awareness and communication about cannabis use. underscoring the need for open, nonjudgmental dialogue and clinical guidance. Although attitudes toward...

Patients with small cell lung cancer (SCLC) and type 1 antineuronal nuclear or “Hu” antibody (ANNA1/Hu-IgG)–related paraneoplastic neurological syndromes (PNS) may experience longer survival, according to the results of a study published in Journal of Neurology. 

According to the results of the phase III POLARGO trial reported by Matasar et al in the Journal of Clinical Oncology, adding polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) significantly improved overall survival compared with standard rituximab, gemcitabine, and ...

On July 22, the U.S. Food and Drug Administration (FDA) approved zidesamtinib (Jideytro), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The approval...

Mapping bone marrow architecture provided a more accurate view of disease state in myelodysplastic neoplasms (MDS) than molecular or blast-based assessments, according to research findings published in Leukemia. The researchers created an AI-based score to assess disease status and changes over...

A research team has reported that a groundbreaking pathway-targeted therapy may be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease. 
 
Martin McMahon, PhD, Senior Director of Preclinical Translation at Huntsman Cancer Institute...

Consolidative thoracic radiotherapy added to standard maintenance immunotherapy increased toxicity without improving survival in first-line extensive-stage small cell lung cancer (SCLC), according to findings from the multicenter phase II TREASURE (AIO-TRK-0320) trial published in JAMA Oncology....

In a cohort study of patients with nonmetastatic colorectal cancer, treatment delays were associated with a higher risk of metastasis, with the magnitude differing by treatment pathway. Nguyen et al published the findings in JAMA Network Open.

Diagnosis of a cancer upon emergency department presentation was associated with an elevated mortality rate, which was consistent across 16 analyzed cancer types, according to new research findings published in the Journal of the National Cancer Institute. 

Elaine S. Jaffe, MD, of the National Cancer Institute (NCI), has won the Association for Molecular Pathology’s (AMP) 2026 Award for Excellence in Molecular Diagnostics.

Researchers have found that with new treatment regimens now available for functional high-risk multiple myeloma, clinicians should use different criteria for identifying patients with poor odds of survival. These findings were published by Ravi et al in the journal Cancer.

As reported in The Lancet Oncology by Siva et al, long-term outcomes of an Australian-Dutch phase II study (TROG 15.03 FASTRACK II) support the safety and local disease control seen with stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma who did not undergo ...

In the long-term follow-up of a Japanese phase II/III trial (JCOG1008) reported in the Journal of Clinical Oncology, Tahara et al found maintained noninferiority of chemoradiotherapy with weekly vs every-3-week cisplatin for overall survival in patients with postoperative high-risk locally advanced ...

A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma (PDAC), according to phase I clinical trial results published by Haidar et al in Cancer Discovery.

Findings from a National Health Interview Survey revealed that civically engaged adults were more likely to stay up to date with their breast cancer screenings. The research findings were published in the American Cancer Society's Cancer journal. 

Based on the results of a population-based, descriptive, cross-sectional study published in JAMA Network Open by Gomez et al, invasive breast cancer incidence rates accelerated among Asian American, Native Hawaiian, and Pacific Islander women over 2 decades.

Oral nicotinamide (vitamin B3) may provide a cost-effective strategy for preventing keratinocyte carcinoma (KC) in persons at high risk, according to a study published in JAMA Dermatology. Led by David Perez, BA, the study was designed to determine whether the clinical benefits previously observed...

In a meta-analysis published in The Oncologist, researchers found that second-generation Bruton's tyrosine kinase (BTK) inhibitors had a better cardiovascular safety profile than the first-generation BTK inhibitor ibrutinib for patients with B-cell malignancies. This led to fewer reported key...

Circulating tumor DNA (ctDNA) for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to findings from an overall survival analysis of the phase II GALAXY...

Researchers have created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The newly published findings provide insights that may explain why patients with similar diagnoses often have differences in disease progression, treatment ...

According to a diagnostic study reported in JAMA Dermatology by Anriot et al, a modern artificial intelligence (AI) foundation model outperformed less experienced clinicians but did not match the diagnostic performance of expert dermatologists when tested under realistic clinical conditions. The...

As reported in The Lancet Oncology by Kaidar-Person et al, an unplanned subset analysis at 20 years in the phase III EORTC trial 22922/10925 showed that internal mammary and medial supraclavicular (IM-MS) nodal irradiation was associated with a significantly lower rate of breast cancer...

Virtual sustained counseling and nicotine replacement therapy led to an almost doubling of 6-month smoking quit rates compared with standard care for patients facing a recent cancer diagnosis, according to findings from the randomized controlled ECOG-ACRIN EAQ171CD trial from the National Cancer...

As reported in The Lancet by Lu et al, an interim analysis of the Chinese phase III HARMONi-6 trial showed that ivonescimab plus chemotherapy was associated with significantly improved overall survival vs tislelizumab plus chemotherapy in patients with previously untreated advanced squamous...

New results from an Alliance Foundation Trials (AFT) study reveal that a simple weekly electronic symptom check-in with the care team significantly improves the quality of life for individuals undergoing treatment for advanced cancer. Researchers found that the biggest improvements were seen among...

In a prospective, multicenter, nonrandomized patient-preference trial published in JAMA Network Open, interval salpingectomy with delayed oophorectomy (ISDO) was associated with less impairment in sexual function than risk-reducing salpingo-oophorectomy (RRSO) among premenopausal women at high risk ...

Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known.

A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort.

All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators.

In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock.

Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP.

The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system.

NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs.

Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source.

A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care.

To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care.

Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success.

Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC).

Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery.

In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU.

Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening.

Advances in multimodal analyses of diverse cell types and cellular products present in the blood have presented opportunities to non-invasively and repeatedly assess systemic immune dynamics, predict and monitor responses to immunotherapies, and detect emerging resistance in patients with cancer. In this Review, the authors discuss various insights on systemic antitumour immune responses that can be gleaned through such liquid biopsy-based analysis of circulating tumour-derived biomarkers and/or immune cells and their implications for immunotherapy.

Interim data from the phase III OptiTROP-Lung05 trial demonstrate that adding the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan to pembrolizumab improves progression-free survival in patients with PD-L1-positive advanced-stage non-small-cell lung cancer. Herein, I present several questions that need to be addressed before this combination can be considered a new standard of care, such as effect on overall survival, long-term safety, global generalizability and biomarker refinement.

Second-line ¹⁷⁷Lu-edotreotide shows promise in GEP NETs

Crossover in trials should not be viewed as confounding, but as informative. Crossover reveals whether deferring therapy produces outcomes comparable to those from earlier use. Statistical crossover-adjustment methods carry unaccounted biases and limited clinical utility. Crossover should instead guide treatment-sequencing decisions, weighing toxicity and cost against any overall survival benefit from earlier intervention.

The future of ciltacabtagene autoleucel in multiple myeloma has just begun

Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma

CRISPR–Cas technologies provide a modular, programmable platform for sequence-specific targeting of DNA or RNA and have advanced from experimental molecular biology tools to clinical translation. This Review describes current and emerging applications of CRISPR–Cas platforms in oncology, including their use in discovery research, diagnostics and therapeutics.

Perioperative chemoimmunotherapy, comprising platinum-doublet chemotherapy plus an anti-PD-(L)1 antibody, has become the standard-of-care approach for patients with resectable non-small-cell lung cancer without an actionable driver alteration. However, the development of this approach has thus far been largely empirical, with limited capacity for adaptation of treatment strategies to better meet the needs of individual patients. In this Review, the authors discuss the potential for improvements in the current approach to perioperative therapy, including de-escalation for those with a pathological complete response, the capacity of various baseline and/or dynamic biomarkers to optimize outcomes, and the potential for escalation in patients with early evidence of a lack of responsiveness in the perioperative setting.

Annals of Internal Medicine, Volume 179, Issue 7, Page 917-928, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 929-937, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 938-947, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 948-957, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 958-967, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 968-979, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 980-987, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 988-995, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 996-1013, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1014-1026, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1027-1029, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1030-1032, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1033-1035, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1036-1042, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1043-1044, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1045-1047, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1048-1050, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1051-1052, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1053-1054, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1056-1059, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1059-1061, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1069, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1069, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1061-1062, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1062-1068, July 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 7, Page 1069-1070, July 2026. <br/>

Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.

Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau candidates from Denali Therapeutics, Eisai and Eli Lilly.

Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.

With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.

A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.

Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.

As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”

Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.

Sanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.

With weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Previously a filing was expected later this year.

Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistically significant.

With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follow to market Ionis Pharmaceuticals’ Tryngolza, which got the regulator’s nod in severe hypertriglyceridemia last month.

With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.

Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.

The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Partners. The readout also represents the second late-stage win for the Merck and Kelun-Biotech asset, called sac-TMT.

Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the brain. However, at the Alzheimer’s Association International Conference on Wednesday, Lilly revealed it is studying the potential of maintenance therapy for patients who need it.

GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.

The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective.

Investment and a maturing talent base have propelled Denmark ahead of its Nordic peers, drawing Swedish companies and exposing regional gaps in capital and scale.

Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be required for Summit and China-based partner Akeso—and other transnational tandems—to secure FDA approval?

Sanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.

With weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Previously a filing was expected later this year.

In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage.

This webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate today’s hiring trends.

Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistically significant.

With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follow to market Ionis Pharmaceuticals’ Tryngolza, which got the regulator’s nod in severe hypertriglyceridemia last month.

With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.

Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.

On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.

On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.

On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC). 

On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.

On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.

On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.

On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.

On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. 

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 

On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 

Pan Afr Med J. 2020 Aug 24;36:329. doi: 10.11604/pamj.2020.36.329.21478. eCollection 2020.
Fenomanana J, Rakotoniaina I, Manantsoa SN, Randriamahenina H, Randriamanantany ZA

Cell. 2026 Jul 17:S0092-8674(26)00752-X. doi: 10.1016/j.cell.2026.06.032.
Wang Z, Jin X, Wu Y, Ding W, Zhang F, Sun Y, Lou F, Bai J, Yang X, Zhou H, Liang J, Cai X, Li Y, Zheng X, Han J, Tong F, Yang Q, Fang Z, Zhao L, Shen Q, Xu Z, Deng S, Fan L, Tong J, Tong L, Wang J, Gao M, Fang Z, Li Q, Chen R, Huang L, Li Z, Yang Y, Zou J, Wu Y, Zhang X, Wang H

Wilderness Environ Med. 2012 Jun;23(2):146-52. doi: 10.1016/j.wem.2012.02.012.
Forrester JA, Holstege CP, Forrester JD

Fam Process. 2022 Sep;61(3):1195-1207. doi: 10.1111/famp.12774. Epub 2022 Apr 7.
Doherty WJ, Harris SM

Front Psychol. 2022 Apr 1;13:800683. doi: 10.3389/fpsyg.2022.800683. eCollection 2022.
Yee AZH, Sng JRH

Science. 2026 Jul 16;393(6808):eaea3075. doi: 10.1126/science.aea3075. Epub 2026 Jul 16.
Tan YJ, Conley TE, Yao F, García-Marqués FJ, Akinyemi DE, Dinh VV, Wang Q, Bermudez A, Kim J, Belk JA, Soehnlein O, Pitteri SJ, Andreasson KI

Acta Diabetol. 2026 May;63(5):775-785. doi: 10.1007/s00592-025-02607-y. Epub 2025 Nov 10.
Singh DR, Malviya S, Sundaram SM

Nature. 2026 Jul 15. doi: 10.1038/s41586-026-10779-y.
Shay JES, Chi F, Tzouanas CN, Han S, Zhang X, Ten Hoeve J, Williams KJ, Neptun S, Sever T, Fuentes I, Bhatia SN, Calibasi-Kocal G, Vander Heiden MG, Shalek AK, Yilmaz ÖH

J Geriatr Phys Ther. 2010 Jan-Mar;33(1):34-40.
Abe T, Sakamaki M, Fujita S, Ozaki H, Sugaya M, Sato Y, Nakajima T

Acta Neurobiol Exp (Wars). 2010;70(2):147-64. doi: 10.55782/ane-2010-1787.
Hewitson L, Lopresti BJ, Stott C, Mason NS, Tomko J

Lancet Public Health. 2026 Jul 20:S2468-2667(26)00141-6. doi: 10.1016/S2468-2667(26)00141-6.
GBD 2023 Road Injuries Collaborators

Science. 2026 Jul 16;393(6808):eady1678. doi: 10.1126/science.ady1678. Epub 2026 Jul 16.
Mattiuz R, Boumelha J, Aerakis E, Le Berichel J, Hamon P, Halasz L, Vaidya A, Soong BY, Radkevich E, Kim HM, Park MD, Donne R, Troncoso L, Kaplan RA, Hennequin C, Hernández-Verdin I, López L, Rentzeperis F, D'Souza D, Kaiza ME, MacFawn IP, Belabed M, Mestrallet G, Humblin E, Merand R, Hegde S, Lone JC, Ioannou G, Ozbey S, Figueiredo I, Tepper A, Merarda H, Serhan N, Schaefer MM, An J, Ohara RA, Nemeth E, Goldstein S, Reid AM, Noureddine M, Tabachnikova A, Piperno GM, Tsoumakidou M, Ahmed J, Polydorides AD, Bhardwaj N, Lujambio A, Chen Z, Gonzalez Kozlova E, Kim-Schulze S, Brody JD, Schotsaert M, Moussion C, Gnjatic S, Roudko V, Ginhoux F, Murphy KM, Sautès-Fridman C, Fridman WH, Brown BD, Marron TU, Benvenuti F, Cyster JG, Salmon H, Bruno TC, Joshi NS, Kamphorst AO, Merad M

Pan Afr Med J. 2020 Nov 25;37:269. doi: 10.11604/pamj.2020.37.269.20556. eCollection 2020.
Sankara P, Djiguimde WP, Ahnoux-Zabsonre A, Sanou J, Meda-Hien G, Diomande IA, Dolo-Traore M, Diallo JW, Bouda GC, Sidibe G

N Engl J Med. 2026 Jul 16;395(3):233-242. doi: 10.1056/NEJMoa2517588.
Tian J, Wang Z, Wang Y, Wang F, Peng X, Xiao J, Li C, Hou X, Tong Q, Yu X, Gao G, Zhao P, Zhao J, Liu Y, Qin Z, Lu H, Zhang S, Li S, Weng Z, Tang H, He Y, Zhang C, Liu Y, Jiang J, Zhang J, Cai L, Xiu L, Mintz GS, Wang D, Stone GW, Yu B; DAPT-MVD Trial Investigators

Nat Rev Gastroenterol Hepatol. 2026 Jul 16. doi: 10.1038/s41575-026-01224-6.
Petrov MS, Yamazaki H, Lu G, Al-Mrabeh AH, Luchini C, Dong X, Hamada T, Liu Y, Oyama H, Rospleszcz S, Chawla S, Shen Y, Cerit ET, Labayen I, Virostko J, Li T, Cadenas-Sanchez C, Alexandre-Heymann L, Albadawy R, Budimir Mršić D, Della Pepa G, Huang Z, Ko J, Li X, Priya S, Souza M; Global Intrapancreatic FaT (GIFT) Alliance

Nature. 2026 Jul 15. doi: 10.1038/s41586-026-10786-z.
Zhang Q, Fu Q, Shen Y, Cao W, Jin G, Zhang Y, Wu J, Chen C, Wang H, Xu X, Sun K, Xue X, Bondanza A, Cao D, Chu N, Durham N, Cobbold M, Farsaci B, Giardino Torchia ML, Hao Y, Hong Y, Huang J, Humphries M, Jian Q, Moody G, Stone J, Sun L, Tu E, Wang F, Wang F, Yang Y, Yao Y, Zou A, Bai X, Liang T

Science. 2026 Jul 16;393(6808):313-318. doi: 10.1126/science.aed6123. Epub 2026 Jul 16.
Skopintsev P, Esain-Garcia I, DeTurk EC, Yoon PH, Zhou Z, Weiss T, Kamalu M, Chamraj A, Loi KJ, Langeberg CJ, Boger RS, Nisonoff H, Karp HM, Chen LX, Shi H, Vohra K, Banfield JF, Cate JHD, Jacobsen SE, Doudna JA

Circulation. 2026 Jul 20. doi: 10.1161/CIR.0000000000001454.
Marcus GM, Hu FB, van Dam RM, Cornelis MC, Dewland TA, Kang J, Larsson SC, Page RL 2nd, Parekh N; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology; and Stroke Council

Microbiology (Reading). 2001 Jan;147(Pt 1):225-37. doi: 10.1099/00221287-147-1-225.
Ramirez-Arcos S, Szeto J, Beveridge T, Victor C, Francis F, Dillon J

Schizophr Res. 2015 Jun;165(1):1-2. doi: 10.1016/j.schres.2015.03.036. Epub 2015 Apr 17.
Fuller Torrey E, Simmons W, Yolken RH